https://www.selleckchem.com/products/astx660.html
BACKGROUND In patients at high risk of opportunistic infections who present with isolated. neurological symptoms, it is lifesaving to consider Central Nervous System Aspergillosis (CNS-A). Ibrutinib use in chronic lymphocytic leukemia (CLL) has previously been associated with CNS-A. We provide a case report of a patient that presented with primary CNS-A on Ibrutinib therapy without any prior pulmonary or local paranasal signs of infection. CASE PRESENTATION 74-year-old Caucasian male with CLL and no prior chemotherapy on ibrutinib for 6
Like
Comment
Share
